(VIANEWS) – Shares of Sorrento Therapeutics (NASDAQ: SRNE) dropped by a staggering 15.15% in 5 sessions from $1.65 at -15.15, to $1.40 at 10:56 EST on Tuesday, after five successive sessions in a row of losses. NASDAQ is jumping 0.06% to $11,030.65, following the last session’s downward trend.
Sorrento Therapeutics’s last close was $1.41, 79.08% under its 52-week high of $6.74.
About Sorrento Therapeutics
Sorrento Therapeutics, Inc. is a commercial and clinical biopharmaceutical firm that develops treatments for neurodegenerative, autoimmune, inflammatory, and cancer. The company operates in two segments: Sorrento Therapeutics, and Scilex. It offers cancer therapy by using its G-MAB antigen library and targeted delivery methods. These include antibody drug conjugate and chimeric antigen- receptor T cell therapy (CAR–T), and dimeric antigen receptor therapy T-cell treatment. The company’s current clinical programs include anti-CD38 CAR–T therapy to treat multiple myeloma and amyloidosis. It produces resiniferatoxin (a non-opioid TRPV1 antagonist neurotoxin) for treatment of late-stage cancers and osteoarthritis. ZTlido is a system that delivers lidocaine for postherpetic neuralgia. SEMDEXA is an injectable viscous jelly formulation that has been developed for treatment of sciatica. SP-103 is an investigational topical lidocaine system for chronic low back pain. SP-104 is a low-dose, delayed-release formulation of naltrexone hydrochloride for the treatment fibromyalgia. SmartPharm Therapeutics Inc. has collaborated with it to create a gene-encoded vaccine against COVID-19. Celularity, Inc. is responsible for initiating the Phase I/II clinical trial, which included up to 94 patients suffering from COVID-19. Mount Sinai Health System will develop COVID-SHIELD, an anti-SARS treatment. Mayo Clinic was involved in Phase Ib pilot studies using sofusa lymphatic drug transport technology to deliver Ipilimumab to delivery to administer Ipilimuma to give Ipilimuma to Ipilimuma to Ipilimumab to Ipilimuma to deliver Ipilimuma to Ipilimumab to Ipilimuma to deliver Ipilimuma. It was established in San Diego in 2006.
Earnings per Share
Sorrento Therapeutics’ trailing 12 months profit per share was $-1.3
For the 12 trailing months, the company’s return-on-equity, which is a measure of the profitability of a company relative to shareholders’ equity, was negative at -206.57%.
Annual Top and Bottom Value
At 10:56 EST Sorrento Therapeutics’ stock was valued at $1.40, which is way lower than its 52 week high of $6.74 but much higher than its low 52-week of $1.15.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions,
Sorrento Therapeutics’s stock is considered to be overbought (>=80).
Sorrento Therapeutics had a negative intraday variation for last week, last year, and quarter. It was negative 5.42%, negative 0.36% and positive 5.34%, respectively.
Sorrento Therapeutics had the highest average volatility amplitudes at 5.42%, 5.32% and 5.34% respectively.
More news about Sorrento Therapeutics (SRNE).